AstraZeneca’s tozorakimab cuts COPD flare-ups by 29-34 percent, offering broad benefits across patients regardless of smoking status or eosinophil levels.
Pharma Today tracks how capital, investment and biosimilars shape new moves across India’s drug industry, with Sun Pharma, ChrysCapital and Lupin advancing distinct growth priorities.
The government panel backs continued home drug delivery, prioritizing medicine access for vulnerable patients while calling for tighter online sales enforcement.
BMS’s third CAR-T bet pays off as arlo-cel shows meaningful response gains in heavily pretreated multiple myeloma patients.
Tylenol exposure in pregnancy draws fresh scrutiny as the latest evidence links prenatal exposure to reproductive changes in daughters.
Lung disease pipeline advances as a cancer combo and PH-ILD drug deliver strong survival, pressure, and functional gains.
Sun Pharma wins investment-grade ratings as its USD 11.75-billion Organon deal strengthens scale, geographic reach and growth opportunities.
Ayurveda seeks to bridge tradition and modern medicine through preventive healthcare, evidence-based research, innovation, and integrative care.
Biocon’s Brazil pact could lower pertuzumab costs for public patients by expanding biosimilar access and supporting local manufacturing.
India’s peptide API race heats up as HRV Pharma commits Rs 150 crore to expand synthetic peptide and high-potency oncology API capacity.
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")